Geron Corp (GERN) presents a deeply negative liquidation recovery posture under standard haircut assumptions. Total reported assets of $534.1M are dominated by inventory ($133.3M) and marketable securities/cash ($270.2M AFS + $68.9M cash + $1.9M restricted cash). Under liquidation haircuts: cash and equivalents recover near par (~$70.8M); AFS marketable securities (high-quality short-duration per filing context) recover near par (~$268M); accounts receivable of $41.9M recovers at 90-95% (~$38-40M); inventory of $133.3M receives a 60% recovery (~$80M), noting the portfolio is 74% WIP/raw materials ($99.1M WIP + $15.6M raw materials) which would likely recover at the low end of that range or below given the highly specialized oligonucleotide manufacturing process and single-indication commercial stage. PP&E of $1.0M recovers at 50-70% (~$0.5-0.7M). The ROU asset ($2.0M) is offset by lease liabilities ($2.2M). Intangibles and goodwill are not separately tagged; RYTELO's IP and regulatory approval carry zero liquidation value. Total estimated liquidation asset recovery: roughly $420-430M. Against total liabilities of $305.0M at face value — including Pharmakon term loan carrying value $165.6M ($170.8M face less $5.2M discount/fees, but face value applies at liquidation), accrued royalties to Royalty Pharma at fair value $129.8M (tagged as LiabilitiesFairValueDisclosure, recorded at $129.8M on balance sheet), current accruals of $73.6M, and long-term purchase commitments of $37.7M (not extinguished on windup) — equity recovery is marginal to negative depending on inventory realization. The $129.8M Royalty Pharma liability is particularly noteworthy: it is marked at fair value, will not extinguish in a simple wind-down, and ranks ahead of equity. The $1.9B accumulated deficit reflects sustained cash consumption. The December 2025 restructuring (approximately one-third workforce reduction, $17M in charges, $13.5M cash paid in Q1 2026) has reduced operating cash burn somewhat, but Q1 2026 operating cash outflow remained $62.9M. The filing does not separately XBRL-tag the Royalty Pharma revenue interest liability as a distinct balance sheet line from AccruedRoyaltiesCurrentAndNoncurrent — the $129.8M appears to be the Royalty Pharma obligation carried at fair value via LiabilitiesFairValueDisclosure, which is a non-standard liability that survives liquidation at its contractual face. MFFAIS CLV of -$125.7M and LLV of -$83.9M are directionally consistent with this analysis. OLV of $49.4M reflects the inventory and receivables book value but does not apply haircuts.
▼ Community Notes